Suven Life Sciences to Showcase CNS Candidates at BIO International Convention 2026

Suven Life Sciences Limited announced its participation in the BIO International Convention 2026 in San Diego, USA, from June 22-25, 2026. The company will showcase its differentiated Central Nervous System (CNS) clinical candidates and explore partnering strategies, out-licensing, and co-development initiatives. Key assets to be highlighted include Ropanicant for major depressive disorder, Masupirdine for agitation in Alzheimer's, and Samelisant for narcolepsy. Suven aims to engage with global pharmaceutical and biotechnology companies through pre-scheduled meetings to accelerate the development and commercialization of its pipeline assets. Senior management and research leaders will be present to discuss advancements and potential collaborations.